The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

There is some good news for fans of Deadliest Catch as a beloved star of the show gave a positive health update. Captain ‘Wild’ Bill Wichrowski shared with fans the latest news following his prostate ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Virginia lawmakers are working on laws to help with breast and prostate cancers, which are the most common in the state.

For the third year in a row, Carver Bank, the largest Black-owned financial institution, brought prostate cancer screenings.

PORTOS can determine which patients with localized prostate cancer will benefit from dose-escalation of radiotherapy, data suggest.

The pharma giant hosted its ninth annual Blue Jacket Fashion Show in collaboration with designer Frederick Anderson in New ...